Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

10.0K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
10.0K
Drug Regulation01:25

Drug Regulation

3.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.2K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

88
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
88
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

337
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
337
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

10.9K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of the HDAC6/8 Inhibitor MC1568, Alone and in Combination With Fluconazole, in Non-Albicans Candida Species Infections.

MicrobiologyOpen·2026
Same author

Probing Chiral Recognition on Amylose Tris(3,5-Dimethylphenylcarbamate) Using Cinnamyl 2-Aminoanilides: The Subtle Impact of Aliphatic Substituents.

Electrophoresis·2026
Same author

Chronic intranasal URB597 treatment reverts short-term memory deficits in a rat model of metabolic syndrome.

Life sciences·2026
Same author

Development of High-Affinity CHD1 Chromodomain Inhibitors.

Journal of medicinal chemistry·2026
Same author

Development of Biphenyl-Substituted Uracil-Based Hydroxamic Acids (UBHAs) as Potent HDAC Inhibitors with Pro-Apoptotic Activity in Leukemia and Prostate Cancer Cells.

Journal of medicinal chemistry·2026
Same author

Combined computational and classical medicinal chemistry procedure to disclose novel pyrrole-based compounds as potential antituberculosis agents.

Journal of computer-aided molecular design·2026

Related Experiment Video

Updated: Apr 20, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.8K

Sirtuin modulators: an updated patent review (2012 - 2014).

Paolo Mellini1, Sergio Valente, Antonello Mai

  • 1Sapienza Università di Roma, Dipartimento di Chimica e Tecnologie del Farmaco , P.le A. Moro 5, 00185 Rome , Italy.

Expert Opinion on Therapeutic Patents
|December 2, 2014
PubMed
Summary

Sirtuin research shows potential for treating aging-related diseases and neurodegeneration. While sirtuin inhibitors are explored for cancer, activators are key for metabolic and inflammatory disorders, with clinical trials underway.

Keywords:
diabetesepigeneticsinflammationobesitysirtuinssmall molecule activators

More Related Videos

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.8K

Related Experiment Videos

Last Updated: Apr 20, 2026

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates
14:32

Deacetylation Assays to Unravel the Interplay between Sirtuins SIRT2 and Specific Protein-substrates

Published on: February 27, 2016

8.8K
Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy
07:40

Protection of H9c2 Myocardial Cells from Oxidative Stress by Crocetin via PINK1/Parkin Pathway-Mediated Mitophagy

Published on: May 26, 2023

1.8K

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Sirtuins (SIRT1-7) are crucial regulators of cellular metabolism, neuroprotection, apoptosis, inflammation, and cancer.
  • SIRT1 is a key target for aging-related diseases and caloric restriction.
  • SIRT modulation offers therapeutic potential for cancer, HIV, muscular diseases, and aging disorders.

Purpose of the Study:

  • To review patents on sirtuin modulation from 2012-2014.
  • To cover therapeutic applications of known and novel sirtuin modulators.
  • To explore sirtuin's role in various disease contexts.

Main Methods:

  • Patent literature review (2012-2014).
  • Analysis of sirtuin modulators and their therapeutic potential.
  • Examination of small molecules targeting sirtuin pathways.

Main Results:

  • Sirtuin's role in cancer remains controversial, with both tumor-promoter and suppressor properties observed.
  • Few SIRT inhibitors were patented between 2012-2014.
  • Sirtuin activators are under intense research for neurodegenerative diseases, metabolic disorders, and inflammation.

Conclusions:

  • Sirtuin activators show promise for treating neurodegenerative, metabolic, and inflammatory conditions.
  • Ongoing clinical trials for SIRT inhibitors and activators suggest future therapeutic applications.
  • Further research is needed to clarify sirtuin's complex role in disease.